Comparison of different treatment regimens in a case of homozygous familial hypercholesterolemia

被引:8
|
作者
Palcoux, JB [1 ]
Meyer, M
Jouanel, T
Vanlieferinghen, P
Malpuech, G
机构
[1] Hop Hotel Dieu, Dept Pediat, F-63058 Clermont Ferrand, France
[2] Hop Hotel Dieu, Biochem Lab, F-63058 Clermont Ferrand, France
来源
THERAPEUTIC APHERESIS | 2002年 / 6卷 / 02期
关键词
familial hypercholesterolemia; low-density lipoprotein apheresis;
D O I
10.1046/j.1526-0968.2002.00345.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The laboratory results of five periods of different treatment regimens were compared in a 19-year-old girl with homozygous familial hypercholesterolemia (FH): weekly low-density lipoprotein (LDL) apheresis sessions with dextran sulfate columns (LA 15, Kaneka Corporation, Osaka, Japan) without statin administration: weekly LDL apheresis with polyacrylate columns (DALI Fresenius Adsorber Technology. Bad Homburg. Germany) without statin: LDL apheresis as in Period 2 with 40 mg atorvastatin daily: LDL apheresis as in Period 2 with 80 mg atorvastatin daily and fortnightly LDL apheresis sessions with polyacrilate and administration of 80 mg atorvastatin daily. The five treatments were given in the above order. and each lasted at least 2 months. To compare the effectiveness of the different methods, the blood levels of total cholesterol. LDL-cholesterol and high-density lipoprotein (HDL)-cholesterol were measured before each session, and the percentage decreases in the blood levels of total cholesterol and LDL-cholesterol were recorded during sessions in Periods 1 and 2. In Periods 1 and 2. the biological effectiveness of LDL apheresis was comparable. Atorvastatin (40 mg daily) improved the blood levels of total cholesterol and LDL-cholesterol. but lowered HDL-cholesterol values. Increasing the daily dose of atorvastatin from 40 mg to 80 mg did not significantly improve LDL-cholesterol levels. When the time between two sessions was longer (Period 5). the total cholesterol and LDL-cholesterol values worsened and were comparable to those of Period 2 during which there was no atorvastatin treatment. In this case of homozygous FH. weekly sessions of LDL apheresis in association with atorvastatin at dose of 40 mg per day gave the best results.
引用
收藏
页码:136 / 139
页数:4
相关论文
共 50 条
  • [1] TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    SHARMA, SK
    KAUSHAL, R
    CHATTOPADHYAY, TK
    BRITISH MEDICAL JOURNAL, 1985, 291 (6509): : 1644 - 1644
  • [2] Treatment of homozygous familial hypercholesterolemia
    France, Michael
    Schofield, Jonathan
    Kwok, See
    Soran, Handrean
    CLINICAL LIPIDOLOGY, 2014, 9 (01) : 101 - 118
  • [3] TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH PROBUCOL
    BAKER, SG
    JOFFE, BI
    MENDELSOHN, D
    SEFTEL, HC
    SOUTH AFRICAN MEDICAL JOURNAL, 1982, 62 (01): : 7 - 11
  • [4] Evinacumab for the treatment of homozygous familial hypercholesterolemia
    Gao, Yanli
    Zhang, Baoqi
    Yang, Junyi
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (02) : 139 - 145
  • [5] PLASMAPHERESIS FOR THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    LURIE, Y
    LAVIE, G
    WYSENBEEK, AJ
    ATSMON, A
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1985, 21 (10): : 871 - 871
  • [6] Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
    Bajaj, Archna
    Cuchel, Marina
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2022, 29 (08) : 1125 - 1135
  • [7] SUCCESS IN THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    RAETZER, H
    OSTER, P
    SCHELLENBERG, B
    SCHLIERF, G
    INNERE MEDIZIN, 1979, 6 (04) : 145 - 148
  • [8] Multimodal Treatment of Homozygous Familial Hypercholesterolemia
    Gossios, Thomas
    Zografou, Ioanna
    Simoulidou, Veta
    Pirpassopoulou, Athina
    Christou, Konstantinos
    Karagiannis, Asterios
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (31) : 3616 - 3621
  • [9] PREGNANCY IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - A CASE SERIES
    Blaha, M.
    Blaha, V.
    Lanska, M.
    Vejrazkova, E.
    Havel, E.
    Vyroubal, P.
    ATHEROSCLEROSIS, 2021, 331 : E132 - E133
  • [10] LIVER TRANSPLANTATION AS A TREATMENT FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Kanmaz, Turan
    Yankol, Yucel
    Karatas, Cihan
    Mecit, Nesimi
    Orug, Taner
    Acarli, Koray
    Kalayoglu, Munci
    PEDIATRIC TRANSPLANTATION, 2011, 15 : 97 - 97